Healthcare
UCB S.A.(UCBJF)
Live Price
Offline$310.00
-0.61% today
1Y Change
+54.62%
Window
Jun 20, 2025 β Jun 8, 2026
- Market Cap
- $43.27B
- Revenue Growth
- +25.8%
- EPS Growth
- +46.2%
- Dividend Yield
- 0.0%
Coverage: 242 bars Β· Jun 20, 2025 β Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
UCB S.A. (UCBJF) is a Healthcare stock with a market cap of $43.27B and listed on OTC. The stock last traded around $310.00 and up 54.6% across the available one-year price window (Jun 20, 2025 β Jun 8, 2026). Baseline metrics include revenue growth of +25.8%, EPS growth of +46.2%, a dividend yield of 0.0%. What stands out right now is revenue +25.8%, EPS +46.2%, free cash flow +104.5% with operating margin 25.3% and ROIC 12.1%. Valuation sits in the middle of the pack at P/E 27.7 and price/sales 5.6. Stock Foundry combines UCBJF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+25.8% vs +7.6% peer median
Operating Margin
Above sector median
+25.3% vs +19.4% peer median
P/E
Below sector median
27.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 26, 2026 with an EPS surprise of +30.2% and a revenue surprise of +1.1%.
The operating story is still moving forward
Revenue is running at +25.8% and EPS at +46.2%, with operating margin around 25.3%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 26, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 26, 2026 | +30.2% | +0.0% | +1.9% | -1.8% |
2025 Jul 31, 2025 | -26.0% | -2.7% | +1.5% | +9.4% |
2025 Feb 27, 2025 | +70.2% | +2.6% | +6.9% | +7.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UCBJF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
UCBJF Max Drawdown
-21.87%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for UCBJF and SPY.
Company Overview
UCB S.A.
Other OTC
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
- Leadership
- Jean-Christophe Tellier
- IPO Date
- Aug 26, 2008
- Employees
- 9.1k
- Street Address
- AllΓ©e de la Recherche, 60
- Mailing
- Brussels, 1070
- Region
- Brussels, BE
- Reporting Currency
- USD
- Investor Line
- 32 2 559 99 99
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 27.7
- EV/EBITDA
- 18.8
- Price/Sales
- 5.6
- Price/Book
- 4.0
Growth
- Revenue
- +25.8%
- EPS
- +46.2%
- Free Cash Flow
- +104.5%
Profitability
- Gross Margin
- 74.3%
- Operating Margin
- 25.3%
- Net Margin
- 20.1%
- ROE
- 15.2%
- ROIC
- 12.1%
Balance Sheet
- Debt/Equity
- 0.21
- Current Ratio
- 1.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.